Albireo Pharma (FRA:BDQM) Institutional Ownership : 46.76% (As of May. 18, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Albireo Pharma's institutional ownership is 46.76%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Albireo Pharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Albireo Pharma's Float Percentage Of Total Shares Outstanding is 76.61%.

Albireo Pharma Institutional Ownership Historical Data

The historical data trend for Albireo Pharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma Institutional Ownership Chart

Albireo Pharma Historical Data

The historical data trend for Albireo Pharma can be seen below:

	2022-05-31	2022-06-30	2022-07-31	2022-08-31	2022-09-30	2022-10-31	2022-11-30	2022-12-31	2023-01-31	2023-02-28
Institutional Ownership	65.14	71.76	71.11	71.96	61.89	61.43	61.66	58.40	50.22	46.76

Albireo Pharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Albireo Pharma (FRA:BDQM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (FRA:BDQM) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

53 State Street, 19th Floor, Boston, MA, USA, 02109

Website

https://www.albireopharma.com

Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Albireo Pharma (FRA:BDQM) Headlines

No Headlines